Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPR3 | P17342 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853134 | 1.00 | ITGA4 (0.53) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL8065025 | 0.84 | MMP8 (0.50) | POLBMMP9ATMALDH1A1 | |
| SCHEMBL8065032 | 0.84 | MMP8 (0.50) | POLBMMP9ATMALDH1A1 | |
| SCHEMBL4443855 | 0.84 | MMP9 (0.49) | ITGA4MMP9ACENPSR1 | |
| SCHEMBL4443858 | 0.84 | MMP9 (0.49) | ITGA4MMP9ACENPSR1 | |
| SCHEMBL4550562 | 0.83 | MMP9 (0.44) | POLBCTSSCTSLCTSBCTSK | |
| SCHEMBL4550561 | 0.83 | MMP9 (0.44) | POLBCTSSCTSLCTSBCTSK | |
| SCHEMBL5163110 | 0.83 | ITGA4 (0.43) | ITGA4ITGB7CTSSCTSLCTSB | |
| SCHEMBL8047919 | 0.81 | ITGA4 (0.46) | ITGA4ITGB7MAPTMMP9ATM | |
| SCHEMBL6667171 | 0.80 | ITGA4 (0.51) | ITGA4ITGB7MAPTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592386-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-22 | — | — | US | claimed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| EP-1144388-B1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARM INC (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1592387-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1592387-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004066932-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-22 | — | — | US | disclosed |
| EP-1147091-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043371-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGA4 6/4885ITGB7 194/4885MAPT 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.